DNA Methylation Profiling Identifies Global Methylation Differences and Markers of Adrenocortical Tumors
Nesrin S. Rechache, Yonghong Wang, Holly S. Stevenson, J. Keith Killian, Daniel C. Edelman, Maria Merino, Lisa Zhang, Naris Nilubol, Constantine A. Stratakis, Paul S. Meltzer, and Electron Kebebew
Endocrine Oncology Section (N.S.R., L.Z., N.N., E.K.), Surgery Branch, Genetics Branch (Y.W., H.S.S., J.K.K., D.C.E., P.S.M.), and Laboratory of Pathology (M.M.), National Cancer Institute, National Institutes of Health, and Section on Endocrinology and Genetics (C.A.S.), Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892
Context: It is not known whether there are any DNA methylation alterations in adrenocortical tumors.
Objective: The objective of the study was to determine the methylation profile of normal adrenal cortex and benign and malignant adrenocortical tumors.
Methods: Genome-wide methylation status of CpG regions were determined in normal (n = 19), benign (n = 48), primary malignant (n = 8), and metastatic malignant (n = 12) adrenocortical tissue samples. An integrated analysis of genome-wide methylation and mRNA expression in benign vs. malignant adrenocortical tissue samples was also performed.
Results: Methylation profiling revealed the following: 1) that methylation patterns were distinctly different and could distinguish normal, benign, primary malignant, and metastatic tissue samples; 2) that malignant samples have global hypomethylation; and 3) that the methylation of CpG regions are different in benign adrenocortical tumors by functional status. Normal compared with benign samples had the least amount of methylation differences, whereas normal compared with primary and metastatic adrenocortical carcinoma samples had the greatest variability in methyl- ation (adjusted P ≤ 0.01). Of 215 down-regulated genes (≥2-fold, adjusted P ≤ 0.05) in malignant primary adrenocortical tumor samples, 52 of these genes were also hypermethylated.
Conclusions: Malignant adrenocortical tumors are globally hypomethylated as compared with normal and benign tumors. Methylation profile differences may accurately distinguish between primary benign and malignant adrenocortical tumors. Several differentially methylated sites are associated with genes known to be dysregulated in malignant adrenocortical tumors. (J Clin Endocrinol Metab 97: E1004-E1013, 2012)
A drenocortical carcinomas (ACC) are rare malignan- cies that have an annual incidence of 0.5-2 cases per million, but adrenal neoplasms are common and are iden- tified in up to 14% of the population (1-4). ACC has a very poor prognosis with only a 15-45% survival at 5 yr (5). The incidence of ACC is highest in the fifth and sixth decade of life; however, a high incidence of ACC has been
found in children in southern Brazil, which was associated with a germline mutation in p53 (6, 7). More than half of ACC are considered functional when excess hormones are produced, and Cushing’s syndrome is the most common clinical manifestation (8, 9). The majority of ACC cases are sporadic; however, several genetic syndromes have been associated with ACC including Beckwith-Wiede-
Abbreviations: ACC, Adrenocortical carcinoma; /GF1R, IGF-I receptor gene; UTR, untrans- lated region.
mann and Li-Fraumeni syndromes, Carney complex, fa- milial adenomatous polyposis, congenital adrenal hyper- plasia, and multiple endocrine neoplasia type 1 (9, 10). Without the clear presentation of local invasion or distant metastasis, the diagnosis and pathological distinction be- tween benign and malignant adrenocortical tumors can be difficult. Histologically, the nine Weiss parameters (0-9 score) are commonly used for diagnosis, with Weiss scores of 2 or less being considered benign and 3 or greater being considered malignant (10). However, given the subjective nature of the Weiss histological features, particularly with regard to scores of 2-3 that are of indeterminate classifi- cation and the most common group of adrenocortical tu- mors, genomic markers that can accurately diagnose ACC, determine prognosis, and shed light on the molec- ular basis of ACC could have important clinical ramifica- tions (8, 11).
Several genetic changes at the chromosomal level (losses and gains) have been found by comparative genomic hybrid- ization in addition to loss of heterozygosity and allelic im- balances in the majority of sporadic ACC cases (6,7, 12). The most common changes are gains at chromosomes 4, 5, 12, and 19 and losses at chromosomes 1, 2, 11, 17, and 22 (6, 7, 12). In addition, high throughput gene expression anal- ysis has confirmed that overexpression of IGF2, a fetal growth factor at the imprinted chromosome 11p15 locus, is an important marker of ACC that is up-regulated in 90% of ACC cases and is regulated by both genetic and epigenetic factors (6, 9, 11, 13). Another important im- printed gene in the 11p15 locus is H19, a non-protein- coding RNA that is thought to inhibit IGF-II expression (12). The autocrine/paracrine growth effects of IGF-II oc- curs via the IGF-I receptor (IGF1R) (12). When IGF-II binds the IGF1R, intracellular networks that affect cell survival and mRNA translation such as the phosphati- dylinositol 3-kinase-AKT-mammalian target of rapa- mycin pathway and proliferation via the RAF-MAPK pathway are activated (14). In addition to p53, IGF2, and H19 have been implicated in the pathogenesis of ACC as well as SF1, GATA6, p57kip2, and MEN1 genes, B-catenin (CTNNB1), and the Wnt and ACTH-cAMP- protein kinase A pathways and other growth factors (TGF, FGF, VEGF, and EGF) (6, 10, 12).
More recently, changes at the epigenetic level have been implicated in carcinogenesis and found to be diagnostic and prognostic markers. Epigenetics refers to heritable changes in gene expression that are not due to changes in DNA. The best defined epigenetic change is DNA meth- ylation of cytosines, by DNA methyltransferase enzymes. Cytosines associated with guanines are called CpG di- nucleotides, and these are generally found in CpG-rich regions called CpG islands. CpG islands are defined as
regions of greater than 500 bp that have guanine cytosine content of greater than 55% (15). Up to 60% of CpG islands are in the 5’ regulatory (promoter) regions of genes (16-18). However, CpG islands that are not in promoter regions can also be found within coding regions and non- coding regions of genes, which may be targets for de novo methylation in cancer and aging (15). DNA methylation affects a number of different cellular processes including apoptosis, cell cycle, DNA damage repair, growth factor response, signal transduction, and tumor architecture, all of which can contribute to the initiation and progression of cancer (19).
To our knowledge, there have been no studies on meth- ylation in ACC. Because of the potential for understanding DNA methylation changes that may be associated with ACC and that differential DNA methylation status may serve as diagnostic markers and or targets for therapy for ACC, we performed genome-wide DNA methylation analysis using a platform with 485,421 cytosine probe sites. We characterized the methylome of 87 adrenocor- tical tissue samples (19 normal, 48 benign, eight primary malignant, and 12 metastatic) and determined the corre- lation of gene-methylation status with gene expression lev- els in benign vs. malignant adrenocortical tissues samples.
Materials and Methods
Tissue samples
Adrenocortical tissue samples were collected as described previously (13,20). Eighty-seven tissue samples were obtained at surgical resection and were immediately snap frozen and stored at -80 C. Normal adrenal glands were obtained at the time of nephrectomy for organ donation and immediately snap frozen and stored at -80 C. Demographic, clinical, and pathological information was collected after written informed consent under an institutional review board approved protocol. Tumors were classified as adrenocortical carcinoma when there was gross lo- cal invasion or distant metastasis was present at diagnosis or developed during follow-up. Benign adrenocortical tissue sam- ples were classified if the tumor was localized at presentation, and there was no evidence of local or distant recurrent disease after follow-up of an average of 2.1 yr (range 1-10 yr) (Table 1).
Methylation profiling of tissue samples
Frozen adrenocortical tissue was sectioned for DNA isola- tion, and total DNA was extracted using DNA STAT-60 (Tel- Test Inc., Friendswood, TX) or DNeasy blood and tissue kit (QIAGEN, Valencia, CA). DNA quality was determined using a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE).
One microgram of DNA was bisulfite converted using the EZ DNA methylation gold kit (Zymo Research Corp., Irvine, CA) according to the manufacturer’s protocol with a modified ther- mocycling procedure as suggested by Illumina (San Diego, CA) (16 cycles of 95 C for 30 sec, 50 C for 60 min). Four microliters
| Benign tumor | Primary tumor | Metastatic tumor | |
|---|---|---|---|
| Number of samples | 48 | 8 | 12 |
| Age (yr), mean ± SEM | 48.9 ± 1.0 | 42.3 ± 5.3 | 57.2 ± 4.8 |
| Gender (women/men) | 35/13 | 5/3 | 11/1 |
| Type of tumor | 48 primary | 8 primary | 7 locoregional recurrence, 2 liver metastases, 2 lung metastases, 1 abdominal wall metastasis |
| Syndrome | |||
| Hypercortisolism | 16 | 6 | 7 |
| Hyperaldosteronism | 16 | 0 | 0 |
| Nonfunctioning | 16 | 2 | 5 |
(~600 ng) of the bisulfite converted DNA were assayed on In- finium HumanMethylation450 BeadChips using the Illumina Infinium HD methylation assay kit (Illumina) (21). These chips assess the methylation status at greater than 485,000 individual CpG sites encompassing 99% of reference sequence genes and 96% of CpG islands (19). Each DNA sample first underwent an overnight isothermal whole-genome amplification step. Ampli- fied DNA was fragmented, precipitated, and resuspended. Sam- ples were hybridized to BeadChips overnight at 48 C in an Illu- mina hybridization oven. Using an automated protocol on the Tecan Evo robot (Tecan Group Ltd., Mannedorf, Switzerland), hybridized arrays were processed through a single-base exten- sion reaction on the probe sequence using DNP- or biotin-labeled nucleotides, with subsequent immunostaining. The BeadChips were then coated, dried, and imaged on an Illumina HiScanSQ. Image data were extracted using the Genome Studio version 2010.3 methylation module (Illumina). Beta values were calcu- lated at each locus (B = intensity of methylated allele/intensity of unmethylated allele + intensity of methylated allele + 100) fol- lowed by analysis with R package to normalize the data. The X and Y chromosomes’ methylation data were excluded from the results. Quality control inclusion valuation depended on hybrid- ization detection P values of less than 0.05. One benign sample failed to meet quality control standards and was thus excluded from subsequent data analysis.
mRNA microarray of tissue samples
Frozen adrenocortical tissue was sectioned for RNA isola- tion, and a serial section was stained using hematoxylin-eosin to confirm diagnosis and tumor content of greater than 80%. Total RNA was extracted from homogenized frozen tissue using Trizol reagent (Invitrogen, Carlsbad, CA) and was purified using an RNeasy minikit (QIAGEN). One microgram of total RNA was used for amplification and labeling with the MessageAmp am- plified RNA kit (Ambion Inc., Foster City, CA). Fragmented and labeled complementary RNA (12 µg) was hybridized to a gene chip (Affymetrix Human Genome U133 plus 2.0 GeneChip; Af- fymetrix Inc., Santa Clara, CA) for16 h at 45 C. The gene chip arrays were stained and washed (Affymetrix Fluidics Station 400; Affymetrix) according to the manufacturer’s protocol. The probe intensities were measured using an argon laser confocal scanner (GeneArray scanner; Hewlett-Packard, Palo Alto, CA).
Data and statistical analyses
Data analysis for the mRNA microarrays was carried out using the Affymetrix GeneChip operating software (Affymetrix) to process the raw microarray data. To generate intensity values in the log2 scale, R/Bioconductor statistics were used for each
probe set using the robust multiarray average method with de- fault variables (22-24). For the class comparison (benign vs. malignant), the limma package in R/Bioconductor was used to calculate the moderated t statistics and the associated P values and the log posterior odds ratio (B statistic) that a gene is dif- ferentially expressed compared with not differentially expressed (25). The P values were adjusted for multiple testing by control- ling for the false discovery rate using the Benjamini-Hochberg method (26).
Data analysis for the methylation BeadChip arrays was car- ried out by extracting image data using the Genome Studio ver- sion 2010.3 methylation module (Illumina). Beta values were calculated at each locus followed by analysis with R package and Partek software (Partek Inc., St. Louis, MO). For the comparison of the different tissue type groups, ANOVA was used based on the M values converted from corresponding beta values from each locus, and P values were adjusted for multiple testing by controlling for the false discovery rate using the Benjamini- Hochberg method (27). Pathway and biological function anal- ysis was conducted using Ingenuity Pathway Analysis software (Ingenuity Systems Inc., Redwood City, CA).
Results
Methylation profile of human adrenocortical tissue samples
Unsupervised hierarchical cluster analysis was per- formed on 19 normal, 47 benign, eight primary malignant, and 12 metastatic tissue samples. Primary malignant ACC and metastatic tissue samples were globally hypomethy- lated compared with normal and benign tissue samples (adjusted P ≤ 0.01) (Fig. 1).
Differentially methylated sites were found in both cod- ing and noncoding regions of DNA. Using an adjusted P ≤ 0.01 and beta value differences of Aß of -0.20 or less or Aß of 0.20 or greater, the smallest methylation differences were found between normal and benign tissue samples (104 total differentially methylated sites), 67.3% of which were hypermethylated in benign tissue samples. The larg- est differences were between primary and metastatic ACC samples compared with normal tissue samples (24,229 and 21,736 differentially methylated sites, respectively), and these were 81.3 and 80.8% hypomethylated in the
Hypomethylated
-2.7
0.8
malignant tissue samples, respectively (Fig. 2A). The next largest differences in methylation patterns were between pri- mary and metastatic ACC samples compared with benign tissue samples (13,727 sites and 11,849 differentially meth- ylated sites, respectively), and these sites were 64.3 and 64.6% hypomethylated in the malignant tissue samples, re- spectively. In contrast, primary ACC samples compared with metastatic samples had only 3799 differentially methylated sites, and these were 59.0% hypermethylated in primary ACC samples (Fig. 2B).
Using principal component analysis to determine the global methylation patterns of 19 normal, 47 benign, eight primary malignant, and 12 metastatic tissue samples and ANOVA with an adjusted P ≤ 0.01, normal and benign adrenocortical tissue samples clustered more closely with less variation. Primary malignant and metastatic tissue samples cluster separately from the normal and benign samples and each other and had greater variability be- tween each sample (Fig. 3).
Analysis of the methylation pattern of benign adreno- cortical tumor samples by functional status (cortisol se- creting, aldosterone secreting, and nonfunctioning) showed different methylation patterns. Aldosterone-se- creting tumor samples compared with nonfunctioning samples had 397 differentially methylated CpG sites (98 hypermethylated, 299 hypomethylated sites). Only eigh- teen differentially methylated CpG sites were found be- tween cortisol-secreting tumor samples compared with al- dosterone-secreting tumor samples, and all of these sites were hypermethylated. We found no significant differ-
ences in the methylation pattern be- tween cortisol secreting tumors and nonfunctioning tumor samples.
Methylation distribution and classification analysis
Methylated cytosines can be in CpG is- lands, shores, shelves, open sea, and sites surrounding transcription sites [-200 to tissue -1500 bp, 5’ untranslated region (UTR), ACC Met. benign and exons 1] for coding genes as well as norm gene bodies and 3’UTR and other/open sea regions derived from genome-wide association studies (28, 29). Shores are considered regions 0-2 kb from CpG is- lands, shelves are regions 2-4 kb from Hypermethylated CpG islands, and other/open sea regions are isolated CpG sites in the genome that 4.2 do not have a specific designation. When comparing the different tissue groups, the benign samples compared with normal tissue samples had the lowest number of methylation CpG probe site differences, but these differences showed the highest percentage of probe sites in other/open sea regions (88%) and the lowest in the island (2%), shore (4%), or shelf (6%) regions. Primary ACC compared with normal, benign, and metastatic tissue sam- ples had a range of 49-61% CpG methylation differences in the other/open sea regions, 13-19% of probes in the island regions, 16-23% in the shores, and 8-10% in the shelves. Similarly, metastatic tissue samples compared with normal and benign samples had a 53-63% number of differentially methylated CpG sites in the intergenic regions, 15-22% within CpG islands, 14-18% in the shores, and 7-8% in the shelves (Fig. 4A).
The CpG sites were then separated based on hyper- methylated or hypomethylated status. Although benign tissue samples compared with normal tissue have the lowest total number of methylation differences, it oc- curs in100% of hypermethylated sites and 65% of hy- pomethylated sites in other/open sea regions. Hyperm- ethylated CpG sites in primary and metastatic ACC samples compared with both normal and benign tissue were predominantly in islands (42-39% for primary and 52% for metastatic ACC tissues), but the hypom- ethylated sites in these two comparisons were predom- inantly in other/open sea regions (70% for primary, 75% for metastatic ACC tissues). In addition, primary ACC compared with the metastatic samples had hyperm- ethylated sites predominantly in the other/open sea region (65%), but the hypomethylated sites were predominantly in shores (34%), islands (31%), and shelves (28%) (Sup-
A
100%
Percent Hyper or Hypomethylation
90%
80%
70%
60%
50%
40%
30%
20%
10%
B
100%
Percent Hyper or Hypomethylation
90%
80%
70%
60%
50%
40%
30%
20%
10%
| 0% | Benign vs Normal | Primary ACC vs Normal | Metastatic ACC vs Normal |
|---|---|---|---|
| Hypomethylation | 34 | 19689 | 17569 |
| Hypermethylation | 70 | 4540 | 4167 |
| 0% | Primary ACC vs Benign | Metastatic ACC vs Benign | Primary ACC vs Metastatic |
|---|---|---|---|
| Hypomethylation | 8824 | 7650 | 1556 |
| Hypermethylation | 4903 | 4199 | 2243 |
FIG. 2. Differential methylation across all tissue comparisons. A, Normal compared with benign tissue samples has the least number of differences in methylation, and they are predominantly hypermethylated (104 total, 34 hypomethylated, and 70 hypermethylated). Primary and metastatic ACC samples compared with normal tissue samples have the greatest number of differences in methylation, and they are predominantly hypomethylated (primary ACC vs. normal, 24,229 total, 19,689 hypomethylated 4,540 hypermethylated, and metastatic vs. normal samples 21,736 total, 17,569 hypomethylated, and 4,167 hypermethylated). B, Primary and metastatic ACC samples compared with benign tissue samples have the next largest differences in methylation, and they are also predominantly hypomethylated (primary ACC vs. benign, 13,727 total, 8,824 hypomethylated, and 4,903 hypermethylated and metastatic vs. benign, 11,849 total, 7,650 hypomethylated, and 4,199 hypermethylated). Primary ACC samples compared with metastatic samples, however, have only 3799 differentially methylated sites, and they are predominantly hypermethylated (1556 hypomethylated and 2243 hypermethylated).
plemental Fig. 1A, published on The Endocrine Society’s Journals Online web site at http://jcem.endojournals.org).
Functional genomic distribution also varied across the tissue comparisons. Although benign and normal tissue samples had the lowest number of methylation probe site differences, the difference in distribution of the CpG sites was the greatest. The differential methylation of probes that distinguished benign from normal tissue samples was highest in the promoter regions of genes (70%) and lowest in the body (23%), 3’UTR (1%) and intergenic regions (7%) compared with other tissue group comparisons. Pri-
mary ACC compared with normal, benign, and metastatic tissue samples had a range of 26-29% of differentially methylated probes in promoter regions, 31-36% in the body, 3-4% in the 3’UTR regions, and 31-47% in inter- genic regions. Metastatic compared with normal and be- nign tissue samples had 25-26% of differentially methyl- ated probes in promoter regions, 30-32% in the body, 3% in the 3’UTR region, and 39-42% in intergenic regions (Fig. 4B).
When the CpG sites were then separated based on hy- permethylated or hypomethylated status, benign com- pared with normal samples had 88% of hypermethylated sites localized in promoter regions and 50% of hypom- ethylated sites in body regions. Primary and metastatic ACC samples compared with normal and benign tissues had most of the hypermethylated sites in promoter (36- 35% primary and 39-37% metastatic respectively), body (33% primary, 31-34% metastatic, respectively) and in- tergenic regions (28% primary, 27-26% metastatic, re- spectively); however, the hypomethylated sites were pre- dominantly in intergenic regions (43-42% primary, 46% metastatic, respectively). Primary compared with meta- static ACC samples, however, had hypermethylated sites that were 38% in intergenic regions and 41% of hypom- ethylated sites in gene bodies (Supplemental Fig. 1B).
RNA coding content compared with other genome con- tent of the differentially methylated probe sites in the com- parisons again showed that although the total number of differentially methylated sites is lowest in benign com- pared with normal samples, these show the highest per- centage distribution in the RNA category (93%), com- pared with other genomic content (7%). Primary ACC tissue samples compared with normal, benign, and met- astatic tissue samples had 59-67% of the differentially methylated sites in RNA coding regions of the genome and 33-41% in other regions. Metastatic compared with nor- mal and benign tissue samples had 56-59% (respectively) differentially methylated probes in RNA coding regions and 41-44% (respectively) in other regions of the genome (Fig. 4C).
Separating the methylation differences in the tissue com- parisons based on hypermethylation or hypomethylation re- vealed that in all tissue comparisons, regardless of methyl- ation status, the predominance of CpG methylation differences were in RNA coding regions. The greatest num- ber of both hyper- and hypomethylated sites in the RNA coding regions were in the benign compared with normal tissue comparison (hypermethylated 97%, hypomethylated 85%). The next largest number of hypermethylated sites in RNA coding regions was in the primary and metastatic ACC compared with normal and benign tissue comparisons (70% primary, 71-72% metastatic, respectively). The hypomethy-
PCA Mapping (44.5%)
360-
291-
tissue
ACC
Met.
222-
benign
norm
153
84
15-
-53
-122-
-191-
-260-
-330-
328
‘908
7.62969
-639
-509
-379
-250
-119
10
140
PC #1 26.7%
lated sites in primary and metastatic ACC compared with normal and benign tissue samples were 56-57% primary and 52% metastatic, respectively. Primary ACC compared with metastatic tissues had hypermethylated sites (60%) and hypomethylated sites (76%) in RNA coding regions (Sup- plemental Fig. 1C).
Unsupervised cluster analysis of primary malignant and benign tissue samples
Because it is sometimes difficult to distinguish between primary malignant and benign adrenocortical neoplasms, we performed an unsupervised hierarchical cluster anal- ysis between these two groups, using data from ANOVA analysis and cutoff values of P ≤ 0.01 and Aß of-0.20 or less or Aß of 0.20 or greater. The primary ACC and benign tissue samples almost completely clustered separately based on their methylation differences with the exception of one ACC sample, which consistently clustered with be- nign tissue samples, and one benign tissue sample, which had extensive necrosis (Supplemental Fig. 2).
Differential methylated regions of chromosomes in primary ACC and benign adrenocortical tumors
Comparative genomic hybrization studies of adreno- cortical tumors have previously shown frequent chromo- somal gains and losses comparing ACC and benign tumors (7, 30). Thus, we analyzed the chromosomal regions that showed differentially methylation between benign and
primary ACC tumor samples using cut- off values of P ≤ 0.01 and Aß of-0.20 or less or Aß of 0.20 or greater. We found clusters of differentially methyl- ated sites in select chromosomal re- gions: hypermethylated regions in pri- mary ACC samples in chromosomes 1q, 2p, 2q, 5p, 6p, 7p, 7q, 10q, 11p, 12p, 12q, 18q, and 21q and hypom- ethylated regions in chromosome 5q and 12q (Supplemental Fig. 3).
Genes differentially methylated between primary malignant and benign adrenocortical samples
Given the difficulty of using histo- pathology in distinguishing benign and malignant samples, we found that 270 400 at the epigenetic level, there were sev- eral differentially methylated probe sites that separated these two categories. With the exception of one ACC sample that clustered with benign tissue samples, all ACC samples had robust differential hypermethylation of probe sites for KCTD12 sites (mean difference across three sites of 2.65, AB = 0.35), KIRREL (mean difference 2.14, AB = 0.34), SYNGR1 (mean difference, 1.65, A = 0.27), and NTNG2 (mean difference 2.50, 4ß = 0.38). Furthermore, other genes implicated in the pathogenesis of ACC such as GATA6 had probe sites that were significantly hypermethylated (mean difference across three sites of 1.99, AB = 0.32). And TP53, and ß-catenin (CTNNB1), each had one site that was hy- pomethylated (mean difference -1.44, Aß = 0.22 and -1.49, AB = 0.21, respectively).
In addition, several hypermethylated CpG sites include those associated with imprinted genes of the chromosome 11p15 locus, including IGF2 and H19 (mean ACC mean benign difference of 1.54, AB = 0.24 and 1.24, 4B = 0.20, respectively). In addition, other genes associated with the IGF-II signaling pathway also had some probe sites that were hypermethylated such as CpG sites associated with IGF1R (mean difference across five probes 1.88, AB = 0.28) and AKT1 (mean difference across four probes, 1.80, AB = 0.25). RARRES2 and SLC16A9, two genes previously found to be robust diagnostic markers for ACC and underexpressed in ACC, were also found to have probe sites that were differentially methylated (13). RARRES2 had hypermethylated CpG sites (mean differ- ence across five probes, 1.75, 4ß = 0.27), and SLC16A9 had hypermethylated sites (mean difference across two sites, 1.70, Aß = 0.26).
A
13% (3112)
ACC vs Normal
16%
(3939)
ACC vs Benign
ACC vs Metastatic
20%
(2749)
Island
19% (2556)
Island
Island
61% (14878)
Shore
53% (7327)
Shore Shelf
49% (1882)
19% (712)
Shore
Shelf
23% (866)
Shelf
10% (2300)
Other
Other
Other
8% (1095)
9%
(339)
Metastatic vs Normal
Metastatic vs Benign
2%
15% (3155)
(2)
Benign vs Normal 4% (4) 6% (6)
14%
(3094)
Island
22% (2655)
Island
Island
63% (13660)
Shore
Shore
Shore
8% (1827)
53% (6313)
Shelf
18% (2066)
Shelf
Other
Other
88% (92)
Shelf
Other
7% (815)
B
ACC vs Normal
ACC vs Benign
ACC vs Metastatic
40% (10042)
26% (6550)
Promoter Body
37% (5274)
27% (3911)
Promoter Body
31% (1261)
29% (1182)
Promoter Body
31% (7745)
3’UTR
3’UTR
Intergenic
33% (4707)
3’UTR
Intergenic
3% (478)
4% (140)
36% (1448)
Intergenic
3%
(860)
Metastatic vs Normal
Metastatic vs Benign
Benign vs Normal 6% (7)
1% (1)
42% (9560)
25%
Promoter Body
39% (4807)
26%
Promoter Body 3’UTR
(5666)
(3304)
23% (25)
Promoter Body
30% (6631)
3’UTR
Intergenic
32% (3942)
70% (77)
3’UTR
Intergenic
Intergenic
3%
3%
(738)
(393)
C
ACC vs Normal
ACC vs Benign
ACC vs Metastatic
41% (10042)
59% (14187)
RNA Other
38% (5274)
33% (1261)
RNA
RNA
62% (8453)
Other
67% (2538)
Other
Metastatic vs Normal
Metastatic vs Benign
Benign vs Normal 7% (7)
44% (9560)
56% (12176)
RNA Other
41% (4807)
59% (7042)
RNA
RNA
Other
93% (97)
Other
Integrated analysis of genome-wide mRNA expression and methylation profile in primary malignant and benign adrenocortical tissue samples
In addition to methylation profiling of primary ACC and benign samples, genome-wide mRNA gene expres-
sion profiling was performed in a subset of samples (five ACC and 74 benign samples). We found 773 probes were differentially expressed (2-fold expres- sion change and adjusted P ≤ 0.05). Of these, 215 were down-regulated genes and 558 were up-regulated. Of the down-regulated genes, 52 were also hy- permethylated (ANOVA adjusted P ≤ 0.01 and 48 ≤-0.20 or AB ≥0.20). Two of these genes, RARRES2 and SLC16A9, were not only both signifi- cantly hypermethylated but also down- regulated in primary ACC samples (-11.98, adjusted P < 0.001, and -12.32, P < 0.001, respectively). GATA6 also had several hypermethy- lated sites and was down-regulated in gene expression (-3.64, adjusted P < 0.001).
When the 52 hypermethylated and down-regulated genes were analyzed using the Ingenuity Systems pathway analysis software, these genes were present in five biological function net- works (Table 2). The network that had the greatest number of genes was the drug metabolism, endocrine system de- velopment and function, lipid metabo- lism biological function pathway, and it contained 16 genes, which were both hypermethylated and down-regulated including RARRES2 and GATA6. The next largest biological function path- way was the lipid metabolism, small molecule biochemistry, cell cycle net- work, which had 12 hypermethylated and down-regulated genes.
Discussion
Our understanding of the molecular events involved in adrenocortical car- cinogenesis is limited, and there have not been studies evaluating the methy- lome of human adrenocortical tissue samples. Thus, we performed methylation profiling of hu- man adrenocortical tissue samples to determine whether epigenetic differences exist in adrenocortical neoplasms and whether this approach could be used for molecular classification as well as to explain the aberrant expression of genes found to be dysregulated in ACC. We found that
| TABLE 2. Biological function pathway analysis networks of hypermethylated and down-regulated genes | ||
|---|---|---|
| Biological function pathway | Score (number of other genes/hypermethylated and down-regulated genes from data sets) | Hypermethylated and downregulated genes (adjusted P < 0.01, B = 0.2; ≥ 2-fold, adjusted P < 0.05) |
| Drug metabolism, endocrine system development and function, lipid metabolism | 38/16 | ABCA1, CD55, CD74, COL4A3, GOS2, GATA6, HSD3B2, KCNQ1, MAP3K5, NCOA7, RAPGEF4, RARRES2, S100A6, SPTBN1, TNFSF13, TNS1 |
| Lipid metabolism, small molecule biochemistry, cell cycle | 27/12 | ADCK3, ALDH3B1, CSDC2, CYP7B1, GIPC2, HOOK1, MEIS1, MLH3, |
| Lipid metabolism, small molecule biochemistry, energy production | 21/10 | MRPL33, NME5, RGNEF, TCIRG1 AMPD3, B4GALT6, CAB39L, CD55, GYPC, NDRG4, RAB34, RBPMS, SEMA6A, TNFS1F2-TNFSF13 |
| Cell-to-cell signaling and interaction, cellular assembly and organization, nervous system development and function | 3/1 | SLC16A9 |
| Hematological disease, immunological disease, infectious disease | 2/1 | PHF11 |
primary and metastatic ACC samples have a global hy- pomethylation pattern compared with normal and benign adrenocortical tissue samples. Moreover, select CpG site methylation status could reliably distinguish between the primary ACC and benign adrenocortical tissue samples. The methylation pattern of normal and benign tissue sam- ples showed strong similarities and homogeneity across the samples, whereas the primary and metastatic tissue samples showed greater variation. There was also a sig- nificant difference in the methylation status of benign tu- mors by the functional status. We also found that clusters of differential methylation patterns in primary ACC and benign tumors samples were located in select chromo- somal regions. In addition, we found that a subset of genes differentially expressed in primary ACC vs. benign adre- nocortical tumors show an association with the methyl- ation status, suggesting that epigenetic regulation of these gene may be an important mechanism.
Although the sequential progression from normal to benign to malignant adrenocortical lesions, as has been demonstrated in colorectal carcinoma, is not well estab- lished, we did observe a greater number of differential methylation from normal to benign to primary ACC to metastatic ACC. On the other hand, although benign sam- ples had the lowest number of methylation CpG probe site differences compared with normal tissue samples, these differences showed the highest percentage of both total and hypermethylated and hypomethylated probe sites in other/open sea regions and the lowest in the island, shore, or shelf regions. Functional genomic distribution also var- ied across the tissue comparisons, and benign compared with normal tissue samples had the highest percentage of total and hypermethylated probes sites in the promoter
regions of genes and lowest total methylated sites in the body, 3’UTR, and intergenic regions compared with other tissue group comparisons. Hypomethylated sites in benign compared with normal tissue samples were highest in body regions, and this was also the highest of all tissue comparisons. Furthermore, the benign compared with normal tissue comparison also showed the highest per- centage distribution of total, hypermethylated, and hy- pomethylated sites in the RNA coding category compared with other genomic content. This suggests that although the methylation differences may be small, they may be in more biologically relevant regions of the genome.
When comparing the methylome of primary malignant and benign adrenocortical tissue samples, a clear signature of differentially methylated probe sites emerged that could classify these two categories. Therefore, determination of the methylation difference in certain probe sites in adre- nocortical tumors may be a useful diagnostic adjunct to histopathology for localized primary ACC. Of the differ- entially methylated genes in primary ACC compared with benign tissue samples, several CpG sites were differentially methylated including those associated with KCTD12, KIRREL, SYNGR1, and NTNG2 and those in the chro- mosome 11p15 imprinted region including IGF2 and H19. In addition, other sites were in the IGF-II pathway, including, IGF1R that IGF-II binds to and AKT1, a down- stream signaling molecule in the cell survival pathway (phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin) of IGF1R. Furthermore, we found other genes associated with ACC such as TP53 and CTNBB1. Both TP53 and CTNBB1 had hypomethylated sites. Fi- nally, RARRES2 and SLC16A9, two previously described
genes that are underexpressed in ACC, also had several hypermethylated sites in ACC tissue samples.
In the integrated genome-wide gene expression and methylation analysis of genes that were both down-regu- lated and hypermethylated, the biological function path- way network analysis revealed that the majority of the genes fell into the drug metabolism, endocrine system de- velopment and function, lipid metabolism network.
The mechanism of methylation alterations is an active area of investigation and may be related to genomic changes among many other factors (31). Although the goal of our study was not to determine the underlying mechanism of methylation alterations, we did find clusters of differentially methylated regions on chromosomes, some of which were in regions previously reported to have frequent genomic gains or losses (1q, 5p, 5q, 6p, 7p, 7q, 12q) in ACC tumor samples (30, 32, 33).
In conclusion, we found distinctly different methyl- ation profiles in human adrenocortical tissue samples between normal, benign, primary malignant, and met- astatic categories. Moreover, methylation profile differ- ences may be able to classify primary ACC and benign adrenocortical tissue samples. Several of the differentially methylated sites were associated with genes known to be dysregulated or altered in ACC. Future gene-specific stud- ies are needed to determine whether the methylation changes we identified regulate ACC initiation and pro- gression and whether hypermethylated and down-regu- lated tumor suppressor genes could be effectively targeted by using demethylating agents.
Acknowledgments
Address all correspondence and requests for reprints to: Electron Kebebew, M.D., 10-CRC/4-5952, 10 Center Drive, Bethesda, Maryland 20892. E-mail: electron.kebebew@nih.gov.
This work was supported by intramural research programs at the National Institutes of Health, National Cancer Institute, Center for Cancer Research, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Disclosure Summary: The authors have nothing to disclose.
References
1. Androulakis II, Kaltsas GA, Markou A, Tseniklidi E, Kafritsa P, Pappa T, Papanastasiou L, Piaditis GP 2011 The functional status of incidentally discovered bilateral adrenal lesions. Clin Endocrinol (Oxf) 75:44-49
2. Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wieand HS 2003 Management of the clinically inapparent ad- renal mass (“incidentaloma”). Ann Intern Med 138:424-429
3. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B,
Chapuis Y, Cougard P, Henry JF, Proye C 2001 Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 25:891-897
4. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B 1995 Incidentally discovered adrenal masses. Endocr Rev 16:460-484
5. Assie G, Guillaud-Bataille M, Ragazzon B, Bertagna X, Bertherat J, Clauser E 2010 The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses. Trends Endocrinol Metab 21:325-334
6. Fassnacht M, Libé R, Kroiss M, Allolio B 2011 Adrenocortical car- cinoma: a clinician’s update. Nat Rev Endocrinol 7:323-335
7. Volante M, Buttigliero C, Greco E, Berruti A, Papotti M 2008 Path- ological and molecular features of adrenocortical carcinoma: an up- date. J Clin Pathol 61:787-793
8. Bussey KJ, Demeure MJ 2009 Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment. Future Oncol 5:641-655
9. Strosberg JR, Hammer GD, Doherty GM 2009 Management of adrenocortical carcinoma. J Natl Compr Canc Netw 7:752-758; quiz 759
10. Soon PS, McDonald KL, Robinson BG, Sidhu SB 2008 Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 13:548-561
11. de Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L, René- Corail F, Dousset B, Bertagna X, Clauser E, Bertherat J 2009 Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and sur- vival. J Clin Oncol 27:1108-1115
12. Bielinska M, Parviainen H, Kiiveri S, Heikinheimo M, Wilson DB 2009 Review paper: origin and molecular pathology of adrenocor- tical neoplasms. Vet Pathol 46:194-210
13. Fernandez-Ranvier GG, Weng J, Yeh RF, Khanafshar E, Suh I, Barker C, Duh QY, Clark OH, Kebebew E 2008 Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch Surg 143:841-846
14. Pollak MN, Schernhammer ES, Hankinson SE 2004 Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518
15. Takai D, Jones PA 2002 Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 99:3740- 3745
16. Bock C, Paulsen M, Tierling S, Mikeska T, Lengauer T, Walter J 2006 CpG island methylation in human lymphocytes is highly cor- related with DNA sequence, repeats, and predicted DNA structure. PLoS Genet 2:e26
17. Esteller M 2008 Epigenetics in cancer. N Engl J Med 358:1148- 1159
18. Jones PA, Baylin SB 2007 The epigenomics of cancer. Cell 128:683- 692
19. Johnstone RW 2002 Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299
20. Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E 2011 MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 117:1630-1639
21. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, Delano D, Zhang L, Schroth GP, Gunderson KL, Fan JB, Shen R 2011 High density DNA methylation array with single CpG site resolution. Genomics 98:288-295
22. Bolstad BM, Irizarry RA, Astrand M, Speed TP 2003 A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193
23. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J 2004 Bioconductor: open software development for computational biol- ogy and bioinformatics. Genome Biol 5:R80
24. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP
2003 Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15
25. Smyth GK 2004 Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article3
26. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I 2001 Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125:279-284
27. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, Lin SM 2010 Comparison of ß-value and M-value methods for quantifying methyl- ation levels by microarray analysis. BMC Bioinformatics 11:587
28. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, Ji H, Potash JB, Sabun- ciyan S, Feinberg AP 2009 The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-spe- cific CpG island shores. Nat Genet 41:178-186
29. Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA,
Bibikova M, Esteller M 2011 Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6:692-702
30. Sidhu S, Marsh DJ, Theodosopoulos G, Philips J, Bambach CP, Campbell P, Magarey CJ, Russell CF, Schulte KM, Röher HD, Del- bridge L, Robinson BG 2002 Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab 87: 3467-3474
31. Cho KS, Elizondo LI, Boerkoel CF 2004 Advances in chromatin remodeling and human disease. Curr Opin Genet Dev 14:308-315
32. Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, Lichter P 2000 Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 28:145-152
33. Stephan EA, Chung TH, Grant CS, Kim S, Von Hoff DD, Trent JM, Demeure MJ 2008 Adrenocortical carcinoma survival rates corre- lated to genomic copy number variants. Mol Cancer Ther 7:425-431
THE ENDOCRINE SOCIETY®
Members can search for endocrinology conferences, meetings, and webinars on the Worldwide Events Calendar.